[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mari Dallas\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100314790","early-phase-1-antigen-specific-adoptive-t-cell-therapy-for-adenovirus-infection-after-hematopoietic-stem-cell-transplantation-100314790",false,"NCT03378102","Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation","Antigen Specific Adoptive T Cell Therapy for Refractory Opportunistic Adenovirus Infection After a Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients must have received allogeneic HSCT and be greater than 30 days post-HSCT at the time of registration.\n* Patients must have evidence of documented HAdV infection\u002Freactivation. Patients may be:\n\n  * Symptomatic with any detectable viral load OR\n  * Asymptomatic with viral load that is:\n\n\\>1000 copies\u002Fml in peripheral blood OR qualitative detection in stool, urine and\u002For other specimens\n\n* Patients must have poor response and\u002For contraindication to therapy:\n\n  * Absence of an improvement of viral load (decrease by at least 1 log, i.e. 10-fold) after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir and\u002For foscarnet. OR\n  * New, persistent and\u002For worsening HAdV-related symptoms, signs and\u002For markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet. OR\n  * Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir, cidofovir or foscarnet.\n* Performance Score: Eastern Cooperative Oncology Group (ECOG) Performance Score ≤ 3. Karnofsky (≥ 16 years) or Lansky (\\\u003C16 years) performance score ≥ 50\n* The effects of virus-specific, antigen-selected T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.\n* Subjects who are 14 years and older must have the ability to understand and the willingness to sign a written informed consent document, or assent document.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women are excluded from this study. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with the agents described above, breastfeeding should be discontinued if the mother participates in this trial.\n* Patients with opportunistic viral infections other than HAdV.\n* Patients with active, grade II-IV, acute graft versus host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\\>0.5 mg\u002Fkg\u002Fday prednisone or its equivalent) as treatment.\n* Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.\n* Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.","ALL","3 Months",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection). This treatment is called adoptive T cell therapy. Another purpose is to learn about the side effects and toxicities of adoptive T cell therapy.\n\nAdoptive T cell therapy is an investigational (experimental) therapy that works by using the blood of a donor that has immunity against the virus. The donor cells are collected and then the cells, called T cells, that are capable of defending against the virus are selected out. These selected T cells are then infused back into the patient, to try to give the immune system the ability to fight the infection. Adoptive T cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).",[26],"Allogeneic Hematopoietic Stem Cell Transplantation",[28,29],"T Cell Therapy","Opportunistic Infection","RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2019-01-04",{"date":38,"type":20},"2028-12",{"name":40,"class":41},"Mari Dallas","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100284461","early-phase-1-t-cell-therapy-of-opportunistic-cytomegalovirus-infection-100284461","NCT02982902","T Cell Therapy of Opportunistic Cytomegalovirus Infection","Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant","Inclusion Criteria:\n\n* Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration\n* Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met)\n\n  * Patients may have asymptomatic viremia (\\>1000 copies\u002Fml) OR presence of symptoms secondary to CMV infection, AND\n  * Patients must have ONE OF THE NEXT FOUR CRITERIA:\n\n    * Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or\n    * New, persistent and\u002For worsening CMV-related symptoms, signs and\u002For markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or\n    * Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet.\n    * Second recurrence of CMV viremia, CMV-related symptoms, signs and\u002For markers of end organ compromise.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3\n* Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document, or assent document.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women are excluded from this study.\n* Patients with opportunistic viral infections other than CMV.\n* Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\\>0.5 mg\u002Fkg\u002Fday prednisone or its equivalent) as treatment\n* Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.\n* Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.\n\nDonor eligibility\n\n* Related donor of T cells must be at least partially HLA compatible, matching with recipient in at least 3\u002F6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this).\n* Must have evidence of a serologic response (i.e. be seropositive) against CMV.\n* Age ≥ 18 years\n* Must meet the criteria for donor selection defined in the Standard Operating Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program\n* Must be capable of undergoing a single standard 2 blood volume leukapheresis or donation of one unit of whole blood",{"count":19,"type":20},[23],"The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV.\n\nAdoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).",[54,55,56],"Cytomegalovirus Infections","Hematopoietic Stem Cell Transplant","Opportunistic Infections",[58,59,60],"Immunotherapy","T-Cell Therapy","Lymphoproliferative Disorder","2025-10-20",{"date":63,"type":34},"2025-10-22",{"date":65,"type":34},"2020-05-27",{"date":67,"type":20},"2028-08",{"name":40,"class":41},""]